BuTrans (buprenorphine) patches are now indicated in the management of non-malignant moderate chronic pain when an opioid is necessary for obtaining adequate analgesia.
The lowest strength (5 microgram/hr) patch should be used initially and the dose may be increased after three days; when the maximum effect of a given dose is established. The dose should be titrated according to the patient's analgesic response to the BuTrans patch and the need for supplemental pain relief.
Further information: Napp
